512 related articles for article (PubMed ID: 26149512)
1. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
Tesar V; Hruskova Z
Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
4. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
[TBL] [Abstract][Full Text] [Related]
5. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
Kallenberg CG
Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
7. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
9. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.
Kallenberg CG; Hauser T
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i119-22. PubMed ID: 25753806
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Lenert A; Lenert P
Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis.
Furuta S; Jayne D
Curr Opin Rheumatol; 2014 Jan; 26(1):1-6. PubMed ID: 24276087
[TBL] [Abstract][Full Text] [Related]
13. Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?
Alba MA; Flores-Suárez LF
Reumatol Clin; 2016; 12(1):39-46. PubMed ID: 26255570
[TBL] [Abstract][Full Text] [Related]
14. B-cell-targeted therapy in systemic vasculitis.
Lally L; Spiera R
Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
[TBL] [Abstract][Full Text] [Related]
15. New Therapeutic Targets in Antineutrophil Cytoplasm Antibody-Associated Vasculitis.
Prendecki M; McAdoo SP
Arthritis Rheumatol; 2021 Mar; 73(3):361-370. PubMed ID: 32562366
[TBL] [Abstract][Full Text] [Related]
16. Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.
Haris Á; Dolgos S; Polner K
Int Urol Nephrol; 2017 Jan; 49(1):91-102. PubMed ID: 27671907
[TBL] [Abstract][Full Text] [Related]
17. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Keogh KA; Wylam ME; Stone JH; Specks U
Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078
[TBL] [Abstract][Full Text] [Related]
18. Management of antineutrophil cytoplasmic antibody-associated vasculitis: a changing tide.
Krishnan A; Walsh M; Collister D
Curr Opin Nephrol Hypertens; 2023 May; 32(3):278-283. PubMed ID: 36811629
[TBL] [Abstract][Full Text] [Related]
19. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis.
Harper L
Curr Opin Rheumatol; 2010 Jan; 22(1):37-42. PubMed ID: 19770660
[TBL] [Abstract][Full Text] [Related]
20. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]